1  Historical Context and Evolution

In 1937, a pharmaceutical company dissolved an antibiotic in antifreeze and killed over 100 people, many of them children. In the 1950s and 1960s, Nazi concentration camp experiments and the Tuskegee syphilis study—where Black men were deliberately left untreated to observe disease progression—exposed the capacity for systematic abuse when research proceeds without ethical constraints. In 1961, thalidomide caused severe birth defects in thousands of infants whose mothers had taken the drug for morning sickness.

Each of these tragedies reshaped the regulatory environment. The sulfanilamide disaster led to the 1938 Food, Drug, and Cosmetic Act requiring safety testing before marketing. The Nazi experiments prompted the Nuremberg Code establishing voluntary consent as essential. Tuskegee led to the Belmont Report and the modern IRB system. Thalidomide led to the 1962 Kefauver-Harris Amendment requiring proof of efficacy, not just safety.

The clinical trial as it exists today—with informed consent, IRB oversight, rigorous protocols, independent monitoring, and regulatory review—emerged from these failures. Every procedural requirement, every form that must be signed, every oversight committee that must approve, exists because at some point in history, research conducted without that protection caused harm. The regulations are not bureaucratic obstacles; they are scar tissue from wounds inflicted on research subjects who had no voice.

1.1 The Elixir Sulfanilamide Disaster (1937)

Prior to the mid-20th century, medical experimentation occurred with minimal regulatory oversight. While many researchers adhered to high ethical standards, the lack of formal requirements created opportunities for abuse and inadequate safety testing.

One of the most significant catalysts for pharmaceutical regulation in the United States was the Elixir Sulfanilamide tragedy of 1937 (U.S. Department of Agriculture 1937). Sulfanilamide was an effective antibacterial drug, but to create a liquid formulation that would appeal to patients who had difficulty swallowing tablets, the S.E. Massengill Company dissolved the drug in diethylene glycol—a sweet-tasting but highly toxic solvent now commonly known as antifreeze.

The consequences were devastating. According to the report from the Secretary of Agriculture to Congress:

“As a result of the distribution of this ‘elixir’ there were over 100 deaths in various parts of the country… The present Federal Food and Drugs Act does not require that new drugs be tested by the manufacturers for the safety of such drugs before they are distributed.” (U.S. Department of Agriculture 1937)

The report revealed critical failures in the drug development process. The chief chemist testified that no tests were made to determine the toxicity of either the separate ingredients or of the finished product (U.S. Department of Agriculture 1937). The “control laboratory” merely checked the elixir for appearance, flavor, and fragrance—not safety. The formula used (see Table 1.1) was:

Table 1.1: Elixir Sulfanilamide Formula (1937)

Ingredient	Amount
Sulfanilamide	58.5 pounds
Diethylene Glycol	60 gallons
Elixir Flavor	1 gallon
Raspberry Extract	1 pint
Saccharin Soluble	1 pound
Water	to make 80 gallons total

The product was labeled simply as “Elixir Sulfanilamide” with no disclosure of diethylene glycol and no warning of danger (U.S. Department of Agriculture 1937). Most of the drug was administered on physicians’ prescriptions. Of the 240 gallons manufactured, approximately half of the 11.5 gallons dispensed was consumed, causing the deaths.

Existing law did not require proof of safety before marketing. Seizures had to be based on a technicality: the word “elixir” implies an alcoholic solution, whereas this product was a diethylene glycol solution. Had it been called a “solution,” no charge of violating the law could have been brought.

The Elixir Sulfanilamide disaster directly led to the passage of the Federal Food, Drug, and Cosmetic Act of 1938, which for the first time required manufacturers to demonstrate the safety of new drugs before they could be marketed.

ImportantKey Regulatory Outcome

The 1938 Act established the principle that new drugs must be proven safe through adequate testing before being marketed—a foundation of modern pharmaceutical regulation.

1.2 The Nuremberg Code (1947)

The atrocities committed by Nazi physicians during World War II represented the darkest chapter in the history of human experimentation. Doctors conducted horrific experiments on concentration camp prisoners without consent, causing immense suffering and death in the name of “medical science.”

Following the war, the Nuremberg Military Tribunals prosecuted 23 German physicians and administrators for war crimes. The tribunal’s judgment included what became known as the Nuremberg Code—ten principles that established the foundational requirements for ethical human experimentation (Nuremberg Military Tribunal 1949; University of North Carolina at Chapel Hill 2024).

The Code’s ten principles address consent, scientific justification, risk minimization, and investigator responsibility. The consent requirement is paramount: subjects must participate voluntarily, with full understanding of the research and its risks. The Code also requires that research have scientific merit and that risks remain proportional to potential benefits. Investigators must be qualified, facilities adequate, and subjects free to discontinue at any time. When evidence suggests harm, the investigator must stop the experiment.

Note

The Nuremberg Code’s emphasis on voluntary consent established the principle that remains central to clinical research ethics today—research subjects must never be coerced and must provide informed consent.

1.3 The Thalidomide Tragedy (1961-1962)

Just over a decade after the Nuremberg Code, another tragedy would reshape pharmaceutical regulation. Thalidomide, a sedative marketed in Europe for sleep and nausea (including morning sickness during pregnancy), caused severe birth defects—primarily phocomelia (limb malformations)—in an estimated 10,000 to 20,000 infants worldwide.

In the United States, FDA medical officer Dr. Frances Kelsey refused to approve thalidomide for marketing, citing insufficient safety data. Her diligence prevented widespread tragedy in America, with only 17 cases reported from investigational use. The contrast was stark: approximately 10,000 affected infants in Europe versus 17 in the United States, demonstrating the critical importance of rigorous regulatory review.

WarningRegulatory Gap Exposed

Thalidomide revealed that proving safety alone was insufficient—drugs also needed to prove efficacy. Additionally, the tragedy highlighted the need for better understanding of drug effects during pregnancy and the importance of systematic adverse event reporting.

The thalidomide tragedy directly led to the Kefauver-Harris Drug Amendments of 1962, which transformed pharmaceutical regulation in several fundamental ways (see Figure 1.1):

The Kefauver-Harris Drug Amendments of 1962 fundamentally transformed pharmaceutical regulation by requiring manufacturers to prove both safety and efficacy before marketing. These amendments mandated that clinical trials be grounded in prior animal studies and established formal requirements for Investigational New Drug (IND) applications. Furthermore, they introduced compulsory reporting for adverse drug reactions and established the critical requirement for informed consent from all research subjects.

timeline
    title Evolution of Clinical Trial Regulation
    1937 : Elixir Sulfanilamide : 100+ deaths
         : FD&C Act of 1938
    1947 : Nuremberg Code : ten principles established
    1961-62 : Thalidomide tragedy : 10,000+ birth defects
           : Kefauver-Harris Amendments
    1964 : Declaration of Helsinki : WMA guidelines
    1974 : National Research Act : NIH oversight
    1979 : Belmont Report : three ethical principles
    1991 : Common Rule : Federal policy unified
    1996 : ICH E6 GCP : Global harmonization

Figure 1.1: Timeline of Major Regulatory Milestones in Clinical Research

1.4 The Declaration of Helsinki (1964)

In 1964, the World Medical Association (WMA) adopted the Declaration of Helsinki, which built upon the Nuremberg Code to provide more detailed ethical guidance specifically for physicians conducting medical research. Unlike the Nuremberg Code, which emerged from criminal proceedings, the Declaration was developed by the medical profession itself as a statement of ethical principles (World Medical Association 2013).

The Declaration of Helsinki made several key contributions to research ethics. It established that research protocols should be reviewed by an independent committee before research begins. It required that research be conducted by scientifically qualified persons. It emphasized that the importance of the research objective must outweigh the risks and burdens to the subject. It called for special protection for research involving vulnerable populations. And it established that researchers have an obligation to publish research results.

The Declaration has been revised multiple times, most recently in 2013, to address emerging ethical issues in clinical research.

1.5 The Tuskegee Syphilis Study (1932-1972)

While regulatory frameworks were evolving for pharmaceutical products, ethical failures in government-sponsored research would expose another critical gap. Between 1932 and 1972, the U.S. Public Health Service conducted the Tuskegee Syphilis Study on approximately 400 low-income African-American males in rural Alabama to observe the natural progression of untreated syphilis.

The study’s ethical violations included:

Ethical violations were systemic: participants were misled into believing they were being treated for “bad blood” rather than syphilis, and even after penicillin became the standard cure in the 1940s, researchers deliberately withheld treatment for four decades. Furthermore, participants were actively obstructed from seeking care through other available health programs, ensuring the natural progression of the disease remained unhindered by clinical intervention.

The revelation of this study in 1972 led directly to major reforms in research ethics and the establishment of systematic oversight mechanisms.

1.6 The Belmont Report (1979)

In response to the Tuskegee study and other ethical violations, the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research produced the Belmont Report in 1979 (National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research 1979). This landmark document established three fundamental ethical principles (Table 1.2) that continue to guide clinical research:

Table 1.2: The Three Principles of the Belmont Report

Principle	Core Requirement	Application to Research
Respect for Persons	Individuals should be treated as autonomous agents; persons with diminished autonomy are entitled to protection	Informed consent: Subjects must voluntarily agree to participate with full understanding of risks, benefits, and alternatives. Vulnerable populations require additional protections.
Beneficence	Do not harm; maximize possible benefits and minimize possible harms	Risk-benefit assessment: Research risks must be reasonable in relation to anticipated benefits. Study design must maximize benefits and minimize risks.
Justice	Fair distribution of research burdens and benefits	Equitable subject selection: The selection of research subjects must be fair. Those who bear the burdens should potentially benefit. Vulnerable groups should not be exploited.

These principles remain the ethical foundation for all human subjects research conducted today. The Belmont Report directly led to the codification of regulations for the protection of human subjects (45 CFR Part 46) and the establishment of Institutional Review Boards (IRBs) to provide independent ethical oversight of research.

1.7 The Common Rule (1991)

The Federal Policy for the Protection of Human Subjects, known as the “Common Rule,” was adopted in 1991 and unified the research protection requirements of 15 federal departments and agencies. Codified at 45 CFR Part 46 for the Department of Health and Human Services, the Common Rule established requirements for Institutional Review Board (IRB) review and approval, requirements for obtaining and documenting informed consent, and protections for specific vulnerable populations including pregnant women, prisoners, and children.

The Common Rule was significantly revised in 2018 to modernize protections while reducing regulatory burden.

1.8 ICH and Global Harmonization (1990s–Present)

As pharmaceutical development became increasingly global, the need for harmonized standards became apparent. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was established in 1990 to bring together regulatory authorities and pharmaceutical industries from Europe, Japan, and the United States.

ICH E6 GCP: Evolution

The ICH Guideline for Good Clinical Practice (E6) was first adopted in 1996 and established an international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials (International Council for Harmonisation 1996). The guideline has evolved significantly through subsequent revisions: E6(R2) in 2016 introduced risk-based monitoring and quality management systems (International Council for Harmonisation 2016), while E6(R3) in 2025 restructured GCP into a Principles document with Annexes, introducing Quality by Design, risk-proportionate oversight, decentralized trial guidance, and technology-neutral data standards (International Council for Harmonisation 2025). This evolution reflects the adaptation of GCP principles to increasingly complex and technology-enabled trial designs.

NoteICH E6(R3) Implementation

The EMA has announced that ICH E6(R3) Principles and Annex 1 will become effective on July 23, 2025 (European Medicines Agency 2024). Annex 2, addressing non-traditional interventional trials, is expected to follow.

The 13 GCP Principles

GCP rests on ethical foundations from the Declaration of Helsinki. The core requirement is that subject welfare takes priority over scientific objectives. Before trials begin, sponsors must demonstrate that preclinical data justify human testing and that risks are reasonable given expected benefits. Trials require clear protocols, qualified investigators, physician oversight of medical decisions, and adherence to approved procedures throughout.

Additional principles cover consent documentation, data integrity, participant confidentiality, drug manufacturing standards, and quality management systems.

1.9 Recent Developments (2020s)

The 2020s pushed clinical trials toward a more technology-enabled, participant-centered, and globally harmonized operating model. COVID-19 forced sponsors and sites to redesign “on the fly” for continuity (remote visits, alternative safety labs, local care, shipment logistics, and documentation of protocol deviations), and FDA codified many of these practices in its guidance on trial conduct during the public health emergency (U.S. Food and Drug Administration 2023b). As pandemic contingencies became durable operating patterns, FDA issued a comprehensive framework for decentralized elements—telehealth and in-home visits, use of local healthcare providers, direct-to-participant investigational product shipment, and electronic consent—explicitly treating decentralization as a set of designable elements rather than an all-or-nothing trial type (U.S. Food and Drug Administration 2024a). In parallel, FDA finalized guidance on using digital health technologies (wearables, sensors, software) for remote data acquisition, with an emphasis on validation/verification, data integrity, and operational controls that make remotely collected endpoints acceptable for regulatory decision-making (U.S. Food and Drug Administration 2023c).

A second shift has been methodological: adaptive and simulation-driven designs moved from “innovative exceptions” to mainstream options for efficiency and decision quality. FDA’s 2019 adaptive design guidance formalized expectations for pre-specified adaptation rules, trial integrity protections, and simulation-based demonstration of operating characteristics (U.S. Food and Drug Administration 2019). International harmonization followed through ICH E20, which standardized vocabulary and best practices for adaptive trials—including the role of simulation, multiplicity control, and operational bias mitigation (International Council for Harmonisation 2024).

Bayesian methods received particular regulatory attention. FDA’s January 2026 draft guidance on Bayesian methodology in clinical trials affirmed that Bayesian approaches are appropriate for primary inference, including in trials that borrow external information (U.S. Food and Drug Administration 2025). The guidance specifies what sponsors must demonstrate:

• pre-specification of Bayesian success criteria
• evaluation of operating characteristics through simulation
• careful justification of prior distributions (especially when borrowing)
• planned sensitivity analyses for prior–data conflict
• documentation sufficient for regulatory review and reproducibility

This framework converts “Bayesian acceptability” from an abstract question into a set of reviewable components—decision rules, error control, effective sample size calculations, and computational reproducibility. The practical result is that sponsors increasingly treat trial design as an iterative engineering exercise, stress-testing decision thresholds across realistic scenarios before the first patient is enrolled.

Another defining theme of the decade has been representation and equity as a regulatory expectation rather than aspirational rhetoric. FDA’s draft guidance on Diversity Action Plans, issued under FDORA, describes when plans are required, what they must contain, how waivers are evaluated, and how sponsors should translate enrollment goals into actionable recruitment and retention strategies (U.S. Food and Drug Administration 2024b). At the same time, the growing use of master protocols and platform approaches—accelerated by COVID-era success stories—has been accompanied by regulatory efforts to standardize expectations around governance, control of multiplicity, and interpretability across continuously evolving trial infrastructures (U.S. Food and Drug Administration 2023d).

Finally, “automation” became a structural response to scale and complexity. Risk-based quality management (RBQM) and centralized monitoring matured into analytics-first oversight models, increasingly supported by statistical anomaly detection and machine learning to prioritize site follow-up, target source data verification, and detect data quality and compliance risks earlier (Association of Clinical Research Organizations 2024). Across the clinical operations stack, AI/ML is being applied to protocol authoring and feasibility, patient-to-trial matching, safety case triage, and Trial Master File processing; the market growth of AI tooling in clinical trials reflects that these capabilities are moving from pilot projects into production workflows (Fortune Business Insights 2024). This trend does not remove the need for human accountability—rather, it shifts effort toward governance, validation, and auditability so automated decisions can be explained and defended.

AI/ML has also reshaped evidence generation, not just operations. The availability of large-scale electronic health record (EHR) and claims datasets made externally controlled analyses and hybrid designs more common, but only when the underlying data are demonstrably “fit for purpose.” FDA’s 2023 guidance on using real-world data (RWD) and real-world evidence (RWE) lays out how sponsors should justify data relevance, reliability, and analytic validity for regulatory decisions (U.S. Food and Drug Administration 2023a). In 2024, FDA finalized more prescriptive guidance on assessing EHR and medical claims sources for regulatory-grade use, reflecting a shift from “RWE is promising” to “RWE is acceptable when you can prove provenance, completeness, linkage quality, and outcome ascertainment” (U.S. Food and Drug Administration 2024c). Practically, this opens the door to more credible external controls, contextualization of single-arm studies, and post-market effectiveness/safety questions—while raising the bar for data engineering, bias assessment, and reproducibility.

A further transition is emerging: from automation as a feature to automation as an operating model. The concept of “agentic AI”—systems that can plan, execute, and verify multi-step workflows rather than simply generate text—is beginning to appear in clinical operations, though governance lags behind capability. The regulatory question is not whether AI can draft a protocol section or flag a safety signal, but whether it can do so in a way that preserves data integrity, produces audit-ready traces, and keeps humans accountable for decisions that affect participant safety. Standards bodies and regulators are adapting: NIST’s AI Risk Management Framework provides a structure for identifying hazards and implementing controls (National Institute of Standards and Technology 2023), while human-AI interaction guidelines emphasize making uncertainty visible and supporting oversight (Amershi et al. 2019). The practical implication is that sponsors deploying AI must now budget for governance—validation, monitoring, and documentation—just as they budget for the software itself.

In Europe, harmonization advanced from principle to infrastructure. The Clinical Trials Regulation (EU) No 536/2014 and the Clinical Trials Information System (CTIS) established a single submission and coordinated assessment process for multinational trials, paired with a public-facing transparency layer; CTIS went live in January 2022, became mandatory for new applications in January 2023, and completed transition requirements for legacy trials by January 2025 (European Medicines Agency 2022).

1.10 The Pattern of Progress

Clinical trial regulation has evolved through a recurring pattern: tragedies expose gaps in protection, public outrage demands action, and legislators respond with new requirements. Table 1.3 summarizes the major inflection points.

Table 1.3: Major Regulatory Milestones in Clinical Research

Year	Event	Regulatory Response
1937	Elixir Sulfanilamide	FD&C Act of 1938 (safety requirement)
1945	Nazi medical experiments	Nuremberg Code (1947)
1961	Thalidomide	Kefauver-Harris Amendments (efficacy requirement)
1972	Tuskegee revelation	National Research Act, Belmont Report
1990s	Global drug development	ICH GCP harmonization
2020s	Pandemic, globalization	DCT guidance, EU CTR, ICH E6(R3)

Today’s clinical trials operate under a framework built from these accumulated lessons. The principles established by the Nuremberg Code, elaborated in the Declaration of Helsinki and Belmont Report, and operationalized in ICH GCP ensure that research is conducted ethically and produces reliable data. The framework continues to evolve—adapting to decentralized trials, AI-driven analytics, and global collaboration—but the core commitment remains unchanged: the welfare of the research subject must always take precedence over the interests of science and society.

Amershi, Saleema, Dan Weld, Mihaela Vorvoreanu, Adam Fourney, Besmira Nushi, Penny Collisson, Jina Suh, et al. 2019. “Guidelines for Human-AI Interaction.” In Proceedings of the 2019 CHI Conference on Human Factors in Computing Systems, 1–13. https://doi.org/10.1145/3290605.3300233.

Association of Clinical Research Organizations. 2024. “ACRO Risk-Based Quality Management Resources.” https://www.acrohealth.org/initiatives-hub/risk-based-quality-management/.

European Medicines Agency. 2022. “Clinical Trials Regulation (EU) No 536/2014 and Clinical Trials Information System (CTIS).” https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/clinical-trials-regulation.

———. 2024. “ICH E6(R3) Good Clinical Practice Guidelines.” https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline.

Fortune Business Insights. 2024. “AI in Clinical Trials Market Size, Share & Industry Analysis.” https://www.fortunebusinessinsights.com/ai-in-clinical-trials-market-114081.

International Council for Harmonisation. 1996. “ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1).” https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r1-guideline-good-clinical-practice_en.pdf.

———. 2016. “ICH E6(R2): Integrated Addendum to ICH E6(R1) - Guideline for Good Clinical Practice.” https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf.

———. 2024. “ICH E20: Adaptive Clinical Trials.” https://www.ema.europa.eu/en/ich-e20-adaptive-designs-clinical-trials-scientific-guideline.

———. 2025. “ICH E6(R3): Guideline for Good Clinical Practice (GCP).” https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf.

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1979. “The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research.” https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/read-the-belmont-report/index.html.

National Institute of Standards and Technology. 2023. “Artificial Intelligence Risk Management Framework (AI RMF 1.0).” https://www.nist.gov/itl/ai-risk-management-framework.

Nuremberg Military Tribunal. 1949. “The Nuremberg Code.” https://collections.nlm.nih.gov/catalog/nlm:nlmuid-01130400RX2-mvpart.

University of North Carolina at Chapel Hill. 2024. “Nuremberg Code.” https://research.unc.edu/human-research-ethics/resources/ccm3_019064/.

U.S. Department of Agriculture. 1937. “Report of the Secretary of Agriculture on Deaths Due to Elixir Sulfanilamide-Massengill.”

U.S. Food and Drug Administration. 2019. “Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry.

———. 2023a. “Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug.

———. 2023b. “COVID-19: Developing Drugs and Biological Products for Treatment or Prevention.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention.

———. 2023c. “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations.

———. 2023d. “Master Protocols for Drug and Biological Product Development: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development.

———. 2024a. “Decentralized Clinical Trials for Drugs, Biological Products, and Devices.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/decentralized-clinical-trials-drugs-biological-products-and-devices.

———. 2024b. “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies.

———. 2024c. “Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory.

———. 2025. “Bayesian Statistics in Medical Device Clinical Trials: Guidance for Industry and FDA Staff.” https://www.fda.gov/media/190505/download.

World Medical Association. 2013. “Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.” https://www.wma.net/policies-post/wma-declaration-of-helsinki/.